See also separate profile for ivacaftor.
- TRADE NAME: Symdeko (Vertex)
- INDICATIONS: Cystic fibrosis in patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene
- CLASS: CFTR potentiator (ivacaftor), CFTR protein corrector (tezacaftor)
- HALF-LIFE: 15 hours (tezacaftor); 14 hours (ivacaftor)
- FDA APPROVAL DATE: 02/12/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Clarithromycin, Erythromycin, Fluconazole, Grapefruit Juice, Itraconazole, Ketoconazole, Phenobarbital, Phenytoin, Posaconazole, Rifabutin, Rifampin, Seville oranges, St John's Wort, Strong CY3PA inducers, Strong or moderate CYP3A inhibitors, Telithromycin, Voriconazole - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
